Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Normal Renal Function Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481

View directory record Official record

Conditions: Normal Renal Function, Impaired Renal Function
Interventions: LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Source: ClinicalTrials.gov public record

Updated Dec 18, 2020 · Synced May 21, 2026, 5:52 PM EDT

Recruiting No phase listed Observational Accepts healthy volunteers

A Natural History Study of Metabolic Sizing in Health and Disease

NCT05398783

View directory record Official record

Conditions: Metabolic Disorders, Cancer, Chronic Kidney Disease, Diabetes, Normal Physiology
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 99 Years

Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

NCT05061979

View directory record Official record

Conditions: Contrast Enhancement in Magnetic Resonance Imaging
Interventions: BAY1747846; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated Nov 20, 2022 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

NCT03506854

View directory record Official record

Conditions: Renal Impairment
Interventions: ISIS 681257; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated May 21, 2019 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

NCT05489614

View directory record Official record

Conditions: Renal Impairment
Interventions: Olpasiran; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Rialto, California • Yucaipa, California • Miami, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Nov 25, 2025 · Synced May 21, 2026, 5:52 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320

View directory record Official record

Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

NCT01309438

View directory record Official record

Conditions: Healthy, Renal Insufficiency
Interventions: Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function), Erythromycin (mild and moderate renal function); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 35 Years to 75 Years

Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Oct 7, 2014 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

NCT06723535

View directory record Official record

Conditions: Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions: BMS-986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 84 Years

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Oct 13, 2025 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05940402

View directory record Official record

Conditions: Renal Impairment
Interventions: Emraclidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Tustin, California • Miami, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 3, 2025 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment

NCT01319266

View directory record Official record

Conditions: Renal Impairment
Interventions: Hydrocodone Bitartrate extended-release tablet; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older

Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 23, 2012 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996

View directory record Official record

Conditions: Advanced Malignancies
Interventions: parsaclisib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 82 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Aug 16, 2022 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

NCT00626249

View directory record Official record

Conditions: Mild Nephropathy, Moderate Nephropathy, Diabetes Mellitus
Interventions: Technosphere Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Omaha, Nebraska • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Dec 16, 2013 · Synced May 21, 2026, 5:52 PM EDT

Terminated Not applicable Interventional Accepts healthy volunteers

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

NCT06456411

View directory record Official record

Conditions: Breast Carcinoma, Kidney Carcinoma, Carcinoma
Interventions: Functional Near-Infrared Spectroscopy, Questionnaire Administration, Virtual Technology Intervention, Cold Stimulation; Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older

Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Apr 28, 2026 · Synced May 21, 2026, 5:52 PM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

NCT01406340

View directory record Official record

Conditions: Anaemia
Interventions: 5 mg GSK1278863; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Source: ClinicalTrials.gov public record

Updated Jun 27, 2019 · Synced May 21, 2026, 5:52 PM EDT

Recruiting Phase 2 Interventional

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661

View directory record Official record

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: AAA617, 68Ga-PSMA-11; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Mar 5, 2026 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

NCT00596518

View directory record Official record

Conditions: Renal Insufficiency, Chronic
Interventions: PF-00734200; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 77 Years

Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Mar 9, 2017 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

NCT01766154

View directory record Official record

Conditions: Renal Insufficiency
Interventions: Tirofiban; Drug
Lead sponsor: Medicure; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Source: ClinicalTrials.gov public record

Updated Mar 26, 2014 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

NCT05117294

View directory record Official record

Conditions: Renal Impairment, Healthy Volunteers
Interventions: Bocidelpar; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anniston, Alabama • Rialto, California • Miami, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Oct 20, 2024 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368

View directory record Official record

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 45
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more

Source: ClinicalTrials.gov public record

Updated Mar 20, 2013 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

NCT06037031

View directory record Official record

Conditions: Renal Impairment
Interventions: Drug: PF-07923568; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years

Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Orlando, Florida • Tampa, Florida • Saint Paul, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 18, 2024 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404

View directory record Official record

Conditions: Renal Impairment
Interventions: Topirmate and Phentermine; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 75 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Anaheim, California • Miami, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Nov 30, 2009 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

NCT05778864

View directory record Official record

Conditions: Renal Insufficiency
Interventions: LY3473329; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Edgewater, Florida • Miami, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Oct 27, 2024 · Synced May 21, 2026, 5:52 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

NCT06729853

View directory record Official record

Conditions: Gout, Hyperuricemia
Interventions: SAP-001; Drug
Lead sponsor: Shanton Pharma Pte. Ltd.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Tampa, Florida • Saint Paul, Minnesota

Source: ClinicalTrials.gov public record

Updated Dec 10, 2024 · Synced May 21, 2026, 5:52 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

NCT00472836

View directory record Official record

Conditions: Obesity
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Anaheim, California • Miami, Florida

Source: ClinicalTrials.gov public record

Updated Aug 12, 2009 · Synced May 21, 2026, 5:52 PM EDT